-
EP2598135
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP2598135
| EP2598135 - TREATMENT OF COGNITIVE DISORDERS WITH CERTAIN ALPHA-7 NICOTINIC ACID RECEPTOR AGONISTS IN COMBINATION WITH ACETYLCHOLINESTERASE INHIBITORS [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 14.10.2016 Database last updated on 31.05.2024 | Most recent event Tooltip | 14.10.2016 | Application deemed to be withdrawn | published on 16.11.2016 [2016/46] | Applicant(s) | For all designated states EnVivo Pharmaceuticals, Inc. 500 Arsenal Street Watertown MA 02472 / US | [2013/29] |
| Former [2013/23] | For all designated states Koenig, Gerhard 1662 Commonwealth Ave. Newton, Massachusetts 02465 / US | ||
| For all designated states Hilt, Dana 204 Clocktower Drive 205 Waltham, Massachusetts 02452 / US | |||
| For all designated states Envivo Pharmaceuticals, Inc. 480 Arsenal Street Bldg. 1 Watertown, MA 02472 / US | Inventor(s) | 01 /
KOENIG, Gerhard 1662 Commonwealth Ave. Newton, Massachusetts 02465 / US | 02 /
HILT, Dana 204 Clocktower Drive 205 Waltham, Massachusetts 02452 / US | [2013/23] | Representative(s) | Holzwarth-Rochford, Andreas Jones Day Nextower Thurn-und-Taxis-Platz 6 60313 Frankfurt am Main / DE | [2013/23] | Application number, filing date | 11748786.8 | 25.07.2011 | WO2011US45206 | Priority number, date | US20100412353P | 10.11.2010 Original published format: US 412353 P | US20100411911P | 09.11.2010 Original published format: US 411911 P | US20100367672P | 26.07.2010 Original published format: US 367672 P | [2013/23] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2012015749 | Date: | 02.02.2012 | Language: | EN | [2012/05] | Type: | A1 Application with search report | No.: | EP2598135 | Date: | 05.06.2013 | Language: | EN | The application published by WIPO in one of the EPO official languages on 02.02.2012 takes the place of the publication of the European patent application. | [2013/23] | Search report(s) | International search report - published on: | EP | 02.02.2012 | Classification | IPC: | A61K31/27, A61K31/439, A61K31/445, A61K31/473, A61K31/55, A61P25/28 | [2013/23] | CPC: |
A61K31/439 (EP,US);
A61K31/27 (EP,US);
A61K31/325 (US);
A61K31/444 (US);
A61K31/445 (EP,US);
A61K31/473 (EP,US);
A61K31/501 (US);
A61K31/55 (EP,US);
A61K45/06 (EP,US);
| C-Set: |
A61K31/27, A61K2300/00 (EP,US);
A61K31/439, A61K2300/00 (US,EP);
A61K31/445, A61K2300/00 (US,EP);
A61K31/473, A61K2300/00 (US,EP); | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2013/23] | Title | German: | BEHANDLUNG VON KOGNITIVEN STÖRUNGEN MIT BESTIMMTEN ALPHA-7-NIKOTINSÄUREREZEPTORAGONISTEN IN KOMBINATION MIT ACETYLCHOLINESTERASEHEMMERN | [2013/23] | English: | TREATMENT OF COGNITIVE DISORDERS WITH CERTAIN ALPHA-7 NICOTINIC ACID RECEPTOR AGONISTS IN COMBINATION WITH ACETYLCHOLINESTERASE INHIBITORS | [2013/23] | French: | TRAITEMENT DE TROUBLES COGNITIFS PAR CERTAINS AGONISTES DU RÉCEPTEUR ALPHA-7 DE L'ACIDE NICOTINIQUE EN COMBINAISON À DES INHIBITEURS D'ACÉTYLCHOLINESTÉRASE | [2013/23] | Entry into regional phase | 22.02.2013 | National basic fee paid | 22.02.2013 | Designation fee(s) paid | 22.02.2013 | Examination fee paid | Examination procedure | deleted | Communication of intention to grant the patent | 22.02.2013 | Amendment by applicant (claims and/or description) | 22.02.2013 | Examination requested [2013/23] | 03.12.2015 | Despatch of a communication from the examining division (Time limit: M06) | 14.06.2016 | Application deemed to be withdrawn, date of legal effect [2016/46] | 12.07.2016 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time [2016/46] | Divisional application(s) | The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 03.12.2015 | Fees paid | Renewal fee | 25.07.2013 | Renewal fee patent year 03 | 14.07.2014 | Renewal fee patent year 04 | 27.07.2015 | Renewal fee patent year 05 | Penalty fee | Additional fee for renewal fee | 31.07.2016 | 06 M06 Not yet paid |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [XI]WO2009018505 (TARGACEPT INC [US], et al) [X] 1-7,25-29 * page 14, paragraph last - page 15, line 4 * * page 53, paragraph last - page 54 * * claims 1-26 * [I] 8-24,30-38; | [XI] - SABBAGH ET AL, "Drug development for Alzheimer's disease: Where are we now and where are we headed?", THE AMERICAN JOURNAL OF GERIATRIC PHARMACOTHERAPY, EXCERPTA MEDICA, vol. 7, no. 3, doi:10.1016/J.AMJOPHARM.2009.06.003, ISSN 1543-5946, (20090601), pages 167 - 185, (20090601), XP026321498 [X] 1-7,25-29 * page 177, column r, paragraph 2 * [I] 8-24,30-38 DOI: http://dx.doi.org/10.1016/j.amjopharm.2009.06.003 | [XI] - BITNER R SCOTT ET AL, "In Vivo Pharmacological Characterization of a Novel Selective alpha 7 Neuronal Nicotinic Acetylcholine Receptor Agonist ABT-107: Preclinical Considerations in Alzheimer's Disease", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, (20100526), vol. 334, no. 3, ISSN 0022-3565, pages 875 - 886 URL, XP055008274 [X] 1-7,25-29 * page 880, column r, paragraph 5 - page 881, column l, paragraph 1 * [I] 8-24,30-38 DOI: http://dx.doi.org/10.1124/jpet.110.167213 | [Y] - REZVANI A H ET AL, "Effect of R3487/MEM3454, a novel nicotinic alpha7 receptor partial agonist and 5-HT3 antagonist on sustained attention in rats", PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, OXFORD, GB, vol. 33, no. 2, doi:10.1016/J.PNPBP.2008.11.018, ISSN 0278-5846, (20090317), pages 269 - 275, (20081213), XP025952929 [Y] 1-38 * Discussion; page 274 * DOI: http://dx.doi.org/10.1016/j.pnpbp.2008.11.018 | [Y] - WALLACE T L ET AL, "R3487/MEM 3454, a novel nicotinic alpha 7 receptor partial agonist, improves attention and working memory performance in cynomolgus macaques", BIOCHEMICAL PHARMACOLOGY, PERGAMON, OXFORD, GB, vol. 78, no. 7, doi:10.1016/J.BCP.2009.06.060, ISSN 0006-2952, (20091001), page 912, (20090813), XP026467517 [Y] 1-38 * the whole document * DOI: http://dx.doi.org/10.1016/j.bcp.2009.06.060 | [Y] - FEUERBACH D ET AL, "The selective nicotinic acetylcholine receptor alpha7 agonist JN403 is active in animal models of cognition, sensory gating, epilepsy and pain", NEUROPHARMACOLOGY, PERGAMON PRESS, OXFORD, GB, vol. 56, no. 1, doi:10.1016/J.NEUROPHARM.2008.08.025, ISSN 0028-3908, (20090101), pages 254 - 263, (20080828), XP025846225 [Y] 1-38 * abstract * DOI: http://dx.doi.org/10.1016/j.neuropharm.2008.08.025 | [Y] - HAUSER T A ET AL, "TC-5619: An alpha7 neuronal nicotinic receptor-selective agonist that demonstrates efficacy in animal models of the positive and negative symptoms and cognitive dysfunction of schizophrenia", BIOCHEMICAL PHARMACOLOGY, PERGAMON, OXFORD, GB, vol. 78, no. 7, doi:10.1016/J.BCP.2009.05.030, ISSN 0006-2952, (20091001), pages 803 - 812, (20090529), XP026467477 [Y] 1-38 * the whole document * DOI: http://dx.doi.org/10.1016/j.bcp.2009.05.030 | Examination | US2005245504 | US2008306081 | by applicant | WO2004029050 | US6780861 | WO2005092890 | US6953855 | US2005245531 | WO2006065233 | WO2007038367 | - HAUSER ET AL., BIOCHEMICAL PHARMACOLOGY, (2009), vol. 78, page 803 | - Handbook of Pharmaceutical Salts, Properties, Selection and Use, WILEY-VCH |